⚙
AI-generated summary
by claude@2026-06, 2026-06-12
ⓘ
This prospective study investigated Dienogest's effects on quality of life and sexual function in women with endometriosis-associated pelvic pain, finding improvements in pain, QoL, sexual function, and sexual distress over 24 months.
⚙
AI-generated deep summary
by claude@2026-06, 2026-06-12
· read from full text
ⓘ
This prospective study evaluated quality of life and sexual function in 54 women with endometriosis-associated pelvic pain treated with dienogest 2 mg daily for 24 months, compared with a control group of 38 women treated with NSAIDs. Pain outcomes (chronic pelvic pain, dysmenorrhea, dyspareunia) were assessed with VAS, while QoL was measured using SF-36 and sexual function/distress using FSFI and FSDS at follow-ups of 3, 6, 12, 18, and 24 months. Slight improvements in pain and early QoL gains appeared by 3 months, with more consistent improvements from 6 to 24 months for QoL, FSFI, and FSDS, whereas the control group showed no change. This paper is centrally about endometriosis—dienogest’s 24-month effects on quality of life and sexual function in women with endometriosis-associated pelvic pain.
Abstract
Salvatore Caruso,1,2 Marco Iraci,1 Stefano Cianci,1 Salvatore Giovanni Vitale,1 Valentina Fava,1,2 Antonio Cianci1,21Department of General Surgery and Medical Surgical Specialties, University of Catania, Catania, Italy; 2Research Group for Sexology, University of Catania, Catania, ItalyPurpose: The aim of this prospective study was to evaluate quality of life (QoL) and sexual function of women affected by endometriosis pain treated with Dienogest (DNG) for 24 months.Patients and methods: Fifty-four women constituted the study group and were given DNG 2 mg/daily; 38 women were given non-steroidal anti-inflammatory drugs (NSAIDs) and constituted the control group. To define endometriosis-associated pelvic pain, dysmenorrhea and dyspareunia the Visual Analogic Scale (VAS) was used. The Short Form-36 (SF-36), the Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale (FSDS) were used to assess the QoL, sexual function and the sexual distress, respectively. The study included five follow-ups at 3, 6, 12, 18 and 24 months.Results: Slight improvements in chronic pelvic pain, dysmenorrhea and dyspareunia were observed in the study group at 3 months (p<0.05) and improved more from 6 to 24 months of DNG treatment (p<0.001). QoL improved with a similar trend: at 3 months the improvement was significant in several categories (p<0.05), and from 6 to 24 months in all categories (p<0.001). The FSFI score did not change at the 3 month follow-up (p=not significant [NS]) but it improved from 6 to 24 months (p<0.001). A similar trend was observed for the FSDS score (p<0.001). No change was observed in the control group (p=NS).Conclusion: Long-term treatment with DNG 2 mg once-daily in women with endometriosis-associated pelvic pain may have positive effects on the QoL and sexual life, confirming the observations of the previous study on the first 6 months of treatment.Keywords: dyspareunia, endometriosis, chronic pelvic pain, long term dienogest, quality of life, sexual life
Full text
2,200 characters
· extracted from
oa-html
· click to expand
Journal of Pain Research (Jul 2019)
Effects of long-term treatment with Dienogest on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain
Abstract
Salvatore Caruso,1,2 Marco Iraci,1 Stefano Cianci,1 Salvatore Giovanni Vitale,1 Valentina Fava,1,2 Antonio Cianci1,21Department of General Surgery and Medical Surgical Specialties, University of Catania, Catania, Italy; 2Research Group for Sexology, University of Catania, Catania, ItalyPurpose: The aim of this prospective study was to evaluate quality of life (QoL) and sexual function of women affected by endometriosis pain treated with Dienogest (DNG) for 24 months.Patients and methods: Fifty-four women constituted the study group and were given DNG 2 mg/daily; 38 women were given non-steroidal anti-inflammatory drugs (NSAIDs) and constituted the control group. To define endometriosis-associated pelvic pain, dysmenorrhea and dyspareunia the Visual Analogic Scale (VAS) was used. The Short Form-36 (SF-36), the Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale (FSDS) were used to assess the QoL, sexual function and the sexual distress, respectively. The study included five follow-ups at 3, 6, 12, 18 and 24 months.Results: Slight improvements in chronic pelvic pain, dysmenorrhea and dyspareunia were observed in the study group at 3 months (p<0.05) and improved more from 6 to 24 months of DNG treatment (p<0.001). QoL improved with a similar trend: at 3 months the improvement was significant in several categories (p<0.05), and from 6 to 24 months in all categories (p<0.001). The FSFI score did not change at the 3 month follow-up (p=not significant [NS]) but it improved from 6 to 24 months (p<0.001). A similar trend was observed for the FSDS score (p<0.001). No change was observed in the control group (p=NS).Conclusion: Long-term treatment with DNG 2 mg once-daily in women with endometriosis-associated pelvic pain may have positive effects on the QoL and sexual life, confirming the observations of the previous study on the first 6 months of treatment.Keywords: dyspareunia, endometriosis, chronic pelvic pain, long term dienogest, quality of life, sexual life
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
is the canonical version.